Premium
Bone morphogenetic protein 6—a possible new player in pathophysiology of heart failure
Author(s) -
Banach Joanna,
Gilewski Wojciech,
Słomka Artur,
Buszko Katarzyna,
Błażejewski Jan,
Karasek Danuta,
Rogowicz Daniel,
Żekanowska Ewa,
Sinkiewicz Wadyslaw
Publication year - 2016
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12665
Subject(s) - medicine , exacerbation , heart failure , cardiology , bone morphogenetic protein 6 , pathophysiology , bone morphogenetic protein 7 , bone morphogenetic protein , biochemistry , chemistry , gene
Summary Derangement of bone morphogenetic protein ( BMP ) signalling was observed in cardiovascular disorders. The present study assesses the diagnostic and prognostic value of BMP 6 plasma concentration in chronic heart failure ( CHF ). 130 CHF patients and 32 controls participated in the study. BMP 6 plasma level was measured at baseline. During 12‐month follow‐up death and hospitalisation with CHF exacerbation were recorded. BMP 6 was significantly increased in CHF patients with highest concentration in most advanced disease. Individuals with pulmonary congestion or peripheral oedema had higher levels of BMP 6 than isovolemic patients. BMP 6 was not a predictor of all‐cause mortality or CHF hospitalisation. BMP 6 may be involved in pathophysiology of systolic CHF . BMP 6 plasma level is related to the disease severity and signs of exacerbation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom